These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22393957)

  • 1. Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat.
    Toniti W; Suthiyotha N; Puchadapirom P; Jenwitheesuk E
    Asian Pac J Cancer Prev; 2011; 12(11):2875-9. PubMed ID: 22393957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence to structure approach of estrogen receptor alpha and ligand interactions.
    Chamkasem A; Toniti W
    Asian Pac J Cancer Prev; 2015; 16(6):2161-6. PubMed ID: 25824732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.
    Lewis-Wambi JS; Kim H; Curpan R; Grigg R; Sarker MA; Jordan VC
    Mol Pharmacol; 2011 Oct; 80(4):610-20. PubMed ID: 21737572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
    Peano BJ; Crabtree JS; Komm BS; Winneker RC; Harris HA
    Endocrinology; 2009 Apr; 150(4):1897-903. PubMed ID: 19022889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
    Wardell SE; Nelson ER; McDonnell DP
    Steroids; 2014 Nov; 90():30-8. PubMed ID: 25084324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.
    Kelly PM; Bright SA; Fayne D; Pollock JK; Zisterer DM; Williams DC; Meegan MJ
    Bioorg Med Chem; 2016 Sep; 24(18):4075-4099. PubMed ID: 27407030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.
    Makar S; Saha T; Swetha R; Gutti G; Kumar A; Singh SK
    Bioorg Chem; 2020 Jan; 94():103380. PubMed ID: 31757413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectively targeting estrogen receptors for cancer treatment.
    Shanle EK; Xu W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1265-76. PubMed ID: 20708050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells.
    Sheng S; Barnett DH; Katzenellenbogen BS
    Mol Cell Endocrinol; 2008 Dec; 296(1-2):1-9. PubMed ID: 18951949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
    Ashtekar SS; Bhatia NM; Bhatia MS
    Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
    McDonnell DP; Wardell SE
    Curr Opin Pharmacol; 2010 Dec; 10(6):620-8. PubMed ID: 20926342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
    Bechmann N; Kniess T; Pietzsch J
    J Med Chem; 2019 Jul; 62(14):6525-6539. PubMed ID: 31099568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
    DuSell CD; Umetani M; Shaul PW; Mangelsdorf DJ; McDonnell DP
    Mol Endocrinol; 2008 Jan; 22(1):65-77. PubMed ID: 17872378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dysregulated Pharmacology of Clinically Relevant
    Andreano KJ; Baker JG; Park S; Safi R; Artham S; Oesterreich S; Jeselsohn R; Brown M; Sammons S; Wardell SE; Chang CY; Norris JD; McDonnell DP
    Mol Cancer Ther; 2020 Jul; 19(7):1395-1405. PubMed ID: 32381587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S
    Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
    Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
    Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.